May 23, 2018 BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that it will enter into an accelerated share repurchase (ASR) program to repurchase $30 million of its outstanding common stock. “Our ASR program reflects Anika’s strong […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone